Physician profile
Anna E Kosentka
NPI 1417968157
$1,183.33
in general payments reported to CMS, 2019-2025
14 companies · $29.28 in 2025
The $29.28 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $328 · 2021: $122 · 2022: $25.13 · 2023: $200 · 2024: $136 · 2025: $29.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285 · Education: $80.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.58 |
| Education | $80.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $387.94 | 2019-2021 | |
| Ucb, INC. | $206.28 | 2019-2024 | Fintepla, Briviact |
| Greenwich Biosciences, INC. | $117.95 | 2019-2020 | |
| Ptc Therapeutics, INC. | $110.83 | 2023 | Emflaza |
| Sarepta Therapeutics, INC. | $63.92 | 2023 | Elevidys |
| Neurelis, INC. | $61.89 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $42.66 | 2019-2021 | |
| Eisai INC. | $41.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.33 | 2019-2021 | |
| Abbvie INC. | $29.28 | 2025 | |
| Amneal Pharmaceuticals LLC | $25.64 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $24.93 | 2023 | Daybue |
| Biogen, INC. | $20.34 | 2019 | |
| Livanova USA, INC. | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kosentka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.